AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Fibrinogen Replacement and Bleeding Trauma Patients: The Cryostat-2 Trial
This chapter discusses the cryostat-2 trial that investigated the use of cryoprecipitate in patients with Massive Hemorrhage Protocol (MHP) activation. The host explores the trial's findings on all-cause 28-day mortality and presents a relevant case to provide context.